XML 87 R42.htm IDEA: XBRL DOCUMENT v3.23.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of Assumptions Used to Determine Fair Value of Options Granted
The fair value of the Company's stock options granted to employees and directors for the years ended December 31, 2022, 2021 and 2020 was estimated using the following assumptions:
202220212020
Expected volatility
29.45%-34.11%
26.21%-27.87%
0.00%-25.79%
Risk free interest rate
1.78%-4.15%
0.30%-0.93%
0.00%-0.86%
Expected dividend$— — — 
Expected term (in years)3.53.53.5
Schedule of Stock Option Activity
A summary of the Company's stock options activity and related information for the year ended December 31, 2022, is as follows:
Number of optionsWeighted-average exercise priceWeighted- average remaining contractual term
(in years)
Aggregate intrinsic
value
Outstanding at January 1, 20221,108,652 21.20 4.42313,083
Granted386,219 13.90
Exercised(213,951)3.58
Cancelled(1,007)27.76
Forfeited(99,941)0.43
Outstanding at December 31, 20221,179,972 23.76 4.31200,905 
Exercisable at December 31, 2022436,520 57.66 2.9060,737 
Schedule of Options Outstanding by Exercise Price Range
The options outstanding under the Company's stock option plans as of December 31, 2022, have been separated into ranges of exercise price as follows:
Ranges of
exercise price
Options outstanding as of December 31, 2022Weighted
average
remaining
contractual
term
Weighted
average
exercise
price
Options Exercisable as of December 31, 2022Weighted
average
exercise
price of
options
exercisable
(Years)$$
$
0.27 - 0.32
1,006,5454.520.29276,7440.29
$
6.82 -7.18
1,5211.047.031,5217.03
$
20.44 - 24.99
2,1594.9821.732,15721.73
$
38.06 - 54.51
3,5343.4545.483,21544.59
$
79.21 - 96.74
47,2590.9788.6947,25988.69
$
151.63 - 224.18
95,3783.79187.1982,048185.52
$
232.20
23,5764.32232.2023,576232.20
1,179,972 4.3123.76 436,520 57.66 
Schedule of Restricted Stock Units Activity
A summary of the Company's RSU and the Company's RSA activities and related information for the year ended December 31, 2022, is as follows:
Number of RSU and
RSA (*)
Outstanding at January 1, 20221,609,009 
Granted684,182 
Vested(626,815)
Forfeited(142,153)
Outstanding at December 31, 20221,524,223 
(*) NIS 1.0 par value, which represents approximately $0.29.
Schedule of Allocated Share-Based Compensation Expense
The total equity-based compensation expense related to all of the Company's equity-based awards recognized for the years ended December 31, 2022, 2021 and 2020 was comprised as follows:
Year ended
December 31,
202220212020
Cost of revenues$18,535 $17,879 $11,313 
Research and development, net39,747 28,558 13,668 
Selling and marketing57,114 42,021 30,262 
General and administrative73,492 67,914 48,221 
Total stock-based compensation expenses$188,888 $156,372 $103,464